Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.

Muskan AgarwalAlex LiuDaniel AlmquistBlake T LanglaisKonstantinos LeventakosNathan Y YuRami ManochakianVinicius Ernani

Published in: Cancer (2023)

The study results demonstrated no significant difference in PFS or OS among the ECOG PS 2-3 and ECOG PS 0-1 groups. Therefore, chemoimmunotherapy should be considered for patients who have ES-SCLC with an ECOG PS of 2-3.

Keyphrases

small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
brain metastases